A current mutation screening program for tailored targeted therapies is also on-going in 1,000 patients with advanced lung adenocarcinoma based on 10 single driver mutations: KRAS (25%), EGFR (23%), ALK rearrangements (6%), BRAF (3%), PIK3CA (3%), MET amplifications (2%), ERBB2 (1%), MEK1 (0.4%), NRAS (0.2%), and AKT1 (<0.1%) [30]. This evidence concerns the gene ALK and lung adenocarcinoma.